Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. The ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nykode Therapeutics Asa is listed on the Euronext Oslo trading with ticker code NYKD.OL. It has a market capitalisation of , with approximately 326.55m shares in issue. Over the last year ...

OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies ...